About neuroendocrine tumors (NETs)
Whether you've been diagnosed with a neuroendocrine tumor (NET)
or your doctor suspects you may have one, you might have questions.
NETs, which are sometimes called "carcinoid tumors" are not as common as
some other cancers. Studies show that about 5 out of every 100,000
people are diagnosed with a NET each year.
So you may not have heard about this type of cancer before and
your doctor may not have seen many patients with NETs in his or her
practice.
This section of the NET Community was developed to help you
better understand this disease. It includes information you can print
out or download to your computer, and videos of patients and physicians
talking about a variety of important NET topics.
What are neuroendocrine tumors (NETs)?
Neuroendocrine tumors, or NETs, are a type of cancer. One way
that NETs are different from other types of cancer is that they aren't
associated with one specific area or organ, such as breast, lung, or
colon cancer. NETs can arise in different tissues and organs throughout
the body that contain neuroendocrine cells.
Neuroendocrine cells are found in the nervous system and the
endocrine system. These 2 systems work together to keep your body
functioning regularly.
The nervous system carries messages from your brain that control
various body functions. Some of these messages are sent to the glands of
the endocrine system. These glands include the pancreas, hypothalamus,
thyroid and parathyroid glands, thymus, pituitary gland, adrenal glands,
ovaries, and testes.
Major glands of the neuroendocrine system
Figure reprinted from
the Merck Manuals Online Library.
The glands of the endocrine system release hormones.
Hormones communicate with specific cells in your body that are involved
in important body functions, such as growth, metabolism, reproduction,
and response to stress or injury. Some neuroendocrine tumors also have
the potential to secrete hormones. These secreting hormones can cause
symptoms and conditions including diabetes, flushing, and diarrhea. This
is another characteristic of NETs that makes them unique among cancers.
Like other types of cells in your body, neuroendocrine cells can
sometimes grow out of control or develop into cancer. This can lead to
serious medical conditions, including neuroendocrine tumors.
What are some of the characteristics of NETs?
There is no one type of neuroendocrine tumor: various types of
NETs can appear and grow differently and affect patients in different
ways.
Although NETs vary in size and how quickly they grow, almost all NETs
are considered to be malignant.
- Malignant tumor cells are considered to be cancer. Malignant
tumors can grow uncontrollably and spread, or metastasize,
to other parts of the body.
- Benign tumors grow slowly or do not grow at all, and they do
not spread to other parts of the body. In some NETs cases the tumors
will be considered benign.
NETs can metastasize to other parts of the
body, most often to the liver or bone.
In fact, by the time they are diagnosed, more than 50% of NETs have
already spread to other parts of the body.There are 3 main reasons for
this delay in diagnosis:
- Some NETs are hard to find until they have grown larger or
spread
- Some NETs don't cause symptoms such as low blood pressure,
diabetes, or pain, until they have grown or spread
- Some NETs cause symptoms that are similar to those caused by
more common conditions, so it may take longer for a NET to be
diagnosed. Most notably, due to the diarrhea associated with carcinoid
syndrome, NETs are often misdiagnosed as IBS, irritable bowel syndrome,
Diabetes can also be caused by a type of NET that occurs in the
pancreas.
Some NETs, however, may be found during routine exams and
diagnosed at an early stage of disease.
Definitions
- Hormone:
- A secreted substance, usually a protein that is transported
through the bloodstream to different organs. Hormones help regulate how
some of the organs in the body work.
- Metastasize:
- To spread from one part of the body to another. The terms
"localized," "regional," and "distant" are sometimes used to describe
how extensively a NET has metastasized.
References
- Yao JC, Hassan M, Phan A, et al. One hundred years after
"carcinoid": epidemiology of and prognostic factors for neuroendocrine
tumors in 35,825 cases in the United States. J Clin Oncol.
2008;26(18):3063-3072.
- Merck Manuals Online Medical Library.
http://www.merckmanuals.com/professional/index.html. 2009. Accessed
December 9, 2010.
- Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical
management of advanced neuroendocrine tumors. Endocr Rev.
2004;25(3):458-511.
- Jensen RT, Doherty GM. Carcinoid tumors and the carcinoid
syndrome. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer:
Principles & Practice of Oncology. 7th ed. Philadelphia, PA:
Lippincott Williams & Wilkins; 2005:1559-1574.
- National Cancer Institute, Dictionary of Cancer Terms.
http://www.cancer.gov/dictionary/. Accessed December 8, 2010.
- Mamikunian G, Vinik AI, O'Dorisio TM, Woltering EA, Go VLW.
Diagnosing and treating gastroenteropancreatic tumors, including ICD-9
codes. In: Neuroendocrine Tumors: A Comprehensive Guide to Diagnosis
and Management. 4th ed. Inglewood, CA: Inter Science Institute;
2009:1-46.
- Banfield A, Green S, Ramage JK. Neuroendocrine tumour
management: a team approach. Hospital Medicine. 2005;66(1):37-42.
- Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current
status of gastrointestinal carcinoids. Gastroenterology.
2005;128(6):1717-1751.
Where do neuroendocrine tumors (NETs) occur?
Many NETs first appear in your gastrointestinal (GI) tract, also called the digestive system. This includes the stomach,
duodenum, appendix, and small and large intestine.
NETs can also appear in your pancreas, lungs, thymus, and other glands.
The site of origin, also referred to as the primary tumor, is one
of the ways that doctors classify NETs. Your doctor may also use terms
such as "GI NET," "pancreatic NET," or "lung NET" to describe your
tumor. Your doctor may also describe your NET as originating in the
"foregut," "midgut," or "hindgut."
Areas in your body where NETs may appear
What are other ways that NETs are classified?
Along with site of origin, there are other ways that doctors
describe and categorize NETs.
Your doctor may talk about your NET in terms of whether it does
or does not secrete hormones. Hormone secretion is a common
characteristic of some types of NETs.
- NETs that secrete hormones are called "functional" tumors
- If a NET secretes large amounts of hormones, it may cause a
variety of symptoms
- NETs that don't produce hormones are called "nonfunctional"
tumors
- These NETs may only cause symptoms due to the tumor's growth,
such as pain, intestinal blockage, or bleeding
Doctors also classify NETs in terms of what they look like under
a microscope (how they are structured). This includes how differentiated
a NET is from the surrounding tissue.
A NET may be described as being "well" or "poorly"
differentiated.
- Well-differentiated NETs can be low or intermediate grade. Low-grade NETs generally grow slowly.
Intermediate-grade NETs are more variable in how they grow.
- Well-differentiated NETs appearing in parts of the digestive
system and lungs traditionally have been called "carcinoids" However,
your doctor may use the term "carcinoid" to describe all types of
NETs. Be sure to ask your doctor to clarify the terms he or she is
using.
- Poorly differentiated NETs are high grade. They generally are
aggressive, and grow and spread rapidly
These factors â where your NET is located, the hormones it
secretes (if any), how far it has spread (if at all), and how aggressive
the tumor is (how fast it may continue to grow or spread) â can help
your doctor develop a management plan for you.
Definitions
- Aggressiveness:
- The speed at which, or the extent to which, a tumor grows and
spreads.
- Differentiation:
- In normal cells, differentiation is the process that changes a
less specialized cell to a more specialized cell type. In tumor cells,
differentiation refers to how developed the cells are. Differentiated
tumor cells resemble normal cells. Undifferentiated or poorly
differentiated tumor cells lack the structure and function of normal
cells. Poorly differentiated tumor cells are considered to have a
greater chance of being malignant.
- Duodenum:
- The first part of the small intestine, connected to the
stomach. The duodenum receives enzymes from the pancreas, along with
chemicals from the liver and the gallbladder, that also aid digestion.
- Gastrointestinal tract:
- Another name for the digestive system, which includes the
mouth, throat, esophagus, stomach, small intestine, large intestine,
rectum, and anus.
- Grade:
- A system of classifying tumor cells. The cells are graded
based on how abnormal they look under a microscope and how quickly the
tumor is likely to grow and spread. Low-grade tumors (grades 1 and 2)
closely resemble surrounding tissue and are less aggressive. High-grade
tumors (grades 3 and 4) do not resemble surrounding tissue and are more
aggressive.
References
- Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current
status of gastrointestinal carcinoids. Gastroenterology.
2005;128(6):1717-1751.
- Yao JC, Hassan M, Phan A, et al. One hundred years after
"carcinoid": epidemiology of and prognostic factors for neuroendocrine
tumors in 35,825 cases in the United States. J Clin Oncol.
2008;26(18):3063-3072.
- Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic
neuroendocrine tumours. Lancet Oncol. 2008;9(1):61-72.
- Klimstra DS, Modlin IR, Adsay NV, et al. Pathology reporting
of neuroendocrine tumors: application of the Delphi Consensus Process
to the development of a minimum pathology data set. Am J Surg Pathol.
2010;34(3):300-313.
- Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The
pathologic classification of neuroendocrine tumors. A review of
nomenclature, grading, and staging systems. Pancreas.
2010;39(6):707-712.
- Strosberg JR, Nasir A, Hodul P, Kvols L. Biology and treatment
of metastatic gastrointestinal neuroendocrine tumors. Gastrointest
Cancer Res. 2008;2(3):113-125.
- National Cancer Institute, Dictionary of Cancer Terms.
http://www.cancer.gov/dictionary/. Accessed December 8, 2010.
- Merck Manuals Online Medical Library.
http://www.merckmanuals.com/professional/index.html. 2009. Accessed
December 9, 2010.
What symptoms are associated with
neuroendocrine tumors (NETs)?
Different types of NETs cause different symptoms. The symptoms
you may experience depend on whether or not your NET is functional or
nonfunctional, and on the location of the tumor.
- Functional NETs produce symptoms caused by the secretion of hormones and other substances
- Nonfunctional NETs do not secrete hormones. They may only
produce symptoms caused by the tumor's growth, such as intestinal
blockage, pain, and bleeding
Some NETs are named based on the hormones they secrete. These
names include "gastrinoma" (gastrin), "glucagonoma" (glucagon), and
"insulinoma" (insulin), and there are several others. NETs also are
sometimes referred to as "carcinoids." Your doctor
may use one of these terms when talking to you about your tumor.
The hormones and other products secreted by functional NETs
sometimes cause clinical syndromes. A syndrome is a set of symptoms that
occur together due to the presence of a disease.
The syndrome caused by a functional NET depends on the hormones
it secretes. Some key types of functional NETs and the syndromes they
may cause are shown in the accompanying table.
Syndromes and symptoms
that may be caused by functional NETs
A closer look at carcinoid syndrome
Carcinoid syndrome occurs in some patients with NETs. It is
associated with the secretion of a hormone called serotonin
and other biochemicals by the tumor.
The symptoms of carcinoid syndrome usually become more noticeable when
the NET starts to grow or spread. This group of symptoms includes:
- Turning red and feeling warm in the face or neck (called
"flushing"), which usually occurs without sweating. This kind of
flushing is different from menopausal flushing that usually comes with
sweating.
- Diarrhea, can often occur at night, which is a clue that
differentiates NETs from IBS, irritable bowel syndrome.
- Abdominal pain
It is important to remember that these symptoms are similar to
those caused by other digestive system disorders, such as irritable
bowel syndrome (IBS). This can make carcinoid syndrome difficult to
diagnose, even for experienced doctors.
Other symptoms and signs of carcinoid syndrome include:
- Wheezing
- Rapid heart rate or palpitations
- Skin lesions or discolored patches of skin
A closer look at pancreatic NETs
Other types of NETs occur in the pancreas. They are known as
pancreatic NETs. They can secrete different kind of hormones that can
cause a variety of symptoms. Click here to find
out more information about pancreatic NETs and the symptoms associated
with them.
However, not all pancreatic NETs are associated with secretion of
hormone products related to clinical symptoms.
Pancreatic NETs are different than other types of pancreatic
cancers. They account for only 1% of all pancreatic cancers. They also
tend to be less aggressive than other types of cancers found in the
pancreas, and patients may generally have a better outlook.
Remember, however, that most pancreatic NETs are considered to be
malignant tumors. So it is important to keep your doctor informed about
all the symptoms you are experiencing, even if you don't think they are
related to your NET.
A closer look at bronchial NETs
In addition to the pancreas, NETs can also originate in the
bronchial system. This includes the lungs and thymus.
Patients with bronchial NETs may experience asthma-like symptoms, such
as coughing and wheezing.
Bronchial NETs vary in how aggressively they grow. Patients
generally have a better outlook than patients with other types of lung
cancers.
Remember, however, that most bronchial NETs are considered to be
malignant tumors. So it is important to keep your doctor informed about
all the symptoms you are experiencing, even if you don't think they are
related to your NET.
Definitions
- Adrenocorticotropic hormone (ACTH):
- A hormone also known as corticotropin that is produced by the
adrenal gland.
- Carcinoid:
- A general term that traditionally has been applied to NETs
that occur in the digestive system or lungs.
- Carcinoid syndrome
- A set of symptoms that occur when a functional NET that
secretes serotonin begins to spread or metastasize. The symptoms may be
sudden or severe.
- Duodenum:
- The first part of the small intestine, connected to the
stomach. The duodenum receives enzymes from the pancreas, along with
chemicals from the liver and the gallbladder, that also aid digestion.
- Gastrin:
- A hormone secreted by the pancreas that signals your stomach
to produce digestive acids and enzymes.
- Glucagon:
- A hormone secreted by the pancreas that raises glucose (sugar)
levels in your blood.
- Growth hormone-releasing factor (GRF):
- A chemical released by the brain that signals the pituitary
gland to produce growth hormone.
- Hormone:
- A secreted substance, usually a protein, that is transported
through the bloodstream to different organs. Hormones help regulate how
some of the organs in the body work.
- Hyperglycemia:
- The condition of having high levels of glucose (sugar) in your
blood. Symptoms include dry mouth; thirst; frequent urination,
including at night; blurry vision; and dry, itchy skin.
- Hypochlorhydria:
- The condition of having low levels of hydrochloric acid in
your stomach. Symptoms include halitosis (bad breath), a metallic taste
in the mouth, heartburn, bloating or belching immediately after eating,
and indigestion.
- Hypoglycemia:
- The condition of having low levels of glucose (sugar) in your
blood. Symptoms include dizziness, headache, fatigue, and confusion.
- Hypokalemia:
- The condition of having low levels of potassium (salt) in your
blood that may be due to excessive diarrhea.
- Insulin:
- A hormone secreted by the pancreas that lowers glucose (sugar)
levels in your blood.
- Lesion:
- An area of abnormal tissue that may or may not be cancerous.
- Pancreas:
- An organ that produces hormones and enzymes that aid in the
digestion of food.
- Pellagra:
- A condition caused by low levels of niacin (a B vitamin) in
your blood. Symptoms include poor appetite and weight loss, diarrhea,
scaly skin rash, mouth ulcers, restlessness, and anxiety.
- Serotonin:
- A hormone made by certain types of cells in the body, mostly
in the gastrointestinal tract. Serotonin helps with various functions,
including reducing gastric secretions and stimulating smooth muscles,
such as those involved in digestion.
- Somatostatin:
- A hormone that stops the release of other hormones, including
gastrin, insulin, and glucagon.
- Thymus:
- An organ near the base of the neck that produces
infection-fighting cells.
- Vasoactive intestinal peptide (VIP):
- A substance secreted by the pancreas that stimulates the
secretion of water and electrolytes in your intestines.
References
- Modlin IM, Moss SF, Chung DC, Jensen RT, Snyderwine E.
Priorities for improving the management of gastroenteropancreatic
neuroendocrine tumors. J Natl Cancer Inst. 2008;100(18):1282-1289.
- Jensen RT, Doherty GM. Carcinoid tumors and the carcinoid
syndrome. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer:
Principles & Practice of Oncology. 6th ed. Philadelphia, PA:
Lippincott Williams & Wilkins; 2001:1559-1574.
- Mamikunian G, Vinik AI, O'Dorisio TM, Woltering EA, Go VLW.
Diagnosing and treating gastroenteropancreatic tumors, including ICD-9
codes. In: Neuroendocrine Tumors: A Comprehensive Guide to Diagnosis
and Management. 4th ed. Inglewood, CA: Inter Science Institute;
2009:1-43.
- Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current
status of gastrointestinal carcinoids. Gastroenterology.
2005;128(6):1717-1751.
- Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr
Relat Cancer. 2004;11(1):1-18.
- Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic
neuroendocrine tumours. Lancet Oncol. 2008;9(1):61-72.
- National Cancer Institute, Dictionary of Cancer Terms.
http://www.cancer.gov/dictionary/. Accessed December 8, 2010.
- Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical
management of advanced neuroendocrine tumors. Endocr Rev.
2004;25(3):458-511.
- Merck Manuals Online Medical Library.
http://www.merckmanuals.com/professional/index.html. 2009. Accessed
December 9, 2010.
- Rorstad O. Prognostic indicators for carcinoid neuroendocrine
tumors of the gastrointestinal tract. J Surg Oncol. 2005;89:151-160.
- National Comprehensive Cancer Network. NCCN Practice
Guidelines in Oncology: Neuroendocrine Tumors. V.2. 2009.
- Grande C, Haller DG. Gastrointestinal stromal tumors and
neuroendocrine tumors. Semin Oncol Nurs. 2009;25(1):48-60.
- Fine KD, Schiller LR. AGA technical review on the evaluation
and management of chronic diarrhea. Gastroenterology.
1999;116(6):1464-1486.
- Wiedenmann B, Pape UF. From basic to clinical research in
gastroenteropancreatic neuroendocrine tumor disease â the
clinician-scientist perspective. Neuroendocrinology. 2004;80(suppl
1):94-98.
- Vinik A, Moattari AR. Use of somatostatin analog in management
of carcinoid syndrome. Dig Dis Sci. 1989;34(3 suppl):14S-27S.
- Yao JC, Eisner MP, Leary C, et al. Population-based study of
islet cell carcinoma. Ann Surg Oncol. 2007;14(12):3492-3500.
- Kulke MH. Clinical presentation and management of carcinoid
tumors. Hematol Oncol Clin N Am. 2007;21:433-455.
- Travis WD, Rush W, Flieder DB,et al. Survival analysis of 200
pulmonary neuroendocrine tumors with clarification of critera for
atypical carcinoid and its separation from typical carcinoid. Am J Surg
Pathol. 1998;22(8):934-944.
- Cooper WA, Thourani VH, Gal AA, Lee RB, Mansour Ka, Miller JI.
The surgical spectrum of pulmonary neuroendocrine neoplasms. Chest.
2001;119(1):14-18.
- Litzky LA. The pathology of nonâÂÂsmall cell carcinoma. In:
Fishman AP, ed. Fishman's Pulmonary Diseases and Disorders. 4th ed. New
York, NY: McGraw-Hill; 2008:1831-1849.
- Farlex Online Medical Dictionary.
http://medical-dictionary.thefreedictionary.com/. Accessed December 8,
2010.
- Medline Plus. Carcinoid tumors.
http://www.nlm.nih.gov/medlineplus/carcinoidtumors.html. Accessed
December 10, 2010.
- Creutzfeldt W. Carcinoid tumors: development of our knowledge.
World J Surg. 1996;20(2):126-131.
What tests are used for neuroendocrine tumors (NETs)?
A number of tests are commonly used to help identify or confirm
the presence of a NET, and to track any changes in your NET that might
occur over time. In some cases, tests can also be used to see how you
are responding to treatment.
These tests include imaging and biochemical tests. Your doctor
may conduct some of them, or you may be referred to a specialist for
others. Your doctor will determine which tests are appropriate for you
and how often you need them.
Imaging tests
Your doctor may use an imaging technique to learn more about
your disease. Imaging tests are used in screening to detect cancer in
its early stages. They are also used to monitor tumor growth and the
effects of treatments. These imaging tests include:
-
Gastrointestinal (GI) probe
A GI endoscopy, or endoscopic ultrasound, is a highly sensitive
ultrasound used to help identify the cause of unexplained GI symptoms.
An endoscopy can also be used as a screening test to check for cancer
or precancerous growths. Endoscopic procedures can also be used to
collect tissue samples, called biopsies, for evaluation.
-
Computed tomography (CT)
Computed tomography is an imaging technique that allows your doctor to
see the shape, size, and position of internal body parts in order to
make a diagnosis.
-
Magnetic resonance imaging (MRI)
Magnetic resonance imaging produces soft-tissue images that allow your
doctor to identify different types of body tissue, and distinguish
normal, healthy tissue from diseased tissue. 
-
Positron emission tomography (PET)
Positron emission tomography is a body imaging technique that can be
useful in identifying neuroendocrine tumors. It uses chemical tracers
to detect whether a tumor is spreading.
-
Octreoscan™
Octreoscan is an imaging technique used to identify specific types of
primary and metastatic neuroendocrine tumors. The procedure involves
being injected with a "tracer" and observed 24 hours later. About 80%
to 90% of NETs can be identified with the specific tracer, called
octreotide, used in this test.
How are these imaging tests different?
MRI is usually used for imaging soft tissue, while CT is the
preferred technique for imaging bone. CT and Octreoscan use a radiation
source, while MRI does not.
Biochemical tests
Your doctor may also perform biochemical testing. Biochemical
tests are for blood, urine, and tissue samples. They include:
-
5-hydroxyindoleacetic acid (5-HIAA)
A 24-hour urine sample test to measure levels of 5-HIAA in your urine.
Elevated levels of 5-HIAA may indicate the presence of a neuroendocrine
tumor, especially those NETs associated with carcinoid syndrome. Your doctor may order the 5-HIAA test along with another test
measuring your blood serotonin level, which can
affect the 5-HIAA test results.
-
Chromogranin A (CgA)
This test measures the amount of a protein in your blood cells called
CgA. Most NETs, whether they are functional or nonfunctional, will secrete CgA. Your doctor may use
CgA testing at diagnosis and to monitor your tumor over time. However,
it is important to be aware that CgA levels can be increased from
certain drugs (such as proton pump inhibitors) or diseases.
-
Neuron-specific enolase (NSE)
NSE is a chemical found in neuroendocrine cells. Your doctor may test
blood or urine samples for levels of NSE and may use other tests along
with NSE to identify a neuroendocrine tumor.
-
Synaptophysin (SNAP)
Synaptophysin is a protein found in blood or tissue samples that can be
used to detect if cancer cells are present. Your doctor may order a
SNAP test along with other tests to confirm a neuroendocrine tumor
diagnosis.
It is important to note that results of biochemical tests are
preliminary. Your doctor should confirm the results with other types of
tests, such as imaging and microscopic analysis of cells and tissue.
It is important to keep accurate records about any tests you've
had scheduled and the results of the tests. Also, ask your doctor about
any changes in your test results and what they mean. Record your
doctor's answers.
Octreoscan is a trademark of Covidien AG or one of
its affiliates.
Definitions
- carcinoid syndrome:
- A set of symptoms that occur when a functional NET that
secretes serotonin begins to spread or metastasize. The symptoms may be
sudden or severe.
- Functional NET:
- A NET that secretes hormones and may cause a variety of
symptoms.
- Nonfunctional NET:
- A NET that doesn't secrete hormones and may only cause
symptoms due to tumor growth.
- Serotonin:
- A hormone made by certain types of cells in the body, mostly
in the gastrointestinal tract. Serotonin helps with various functions,
including reducing gastric secretions and stimulating smooth muscles,
such as those involved in digestion.
References
- Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current
status of gastrointestinal carcinoids. Gastroenterology.
2005;128(6):1717-1751.
- Ferolla P, Faggiano A, Mansueto G, et al. The biological
characterization of neuroendocrine tumors: the role of neuroendocrine
markers. J Endocrinol Invest. 2008;31(3):277-286.
- Strosberg JR, Nasir A, Hodul P, Kvols L. Biology and treatment
of metastatic gastrointestinal neuroendocrine tumors. Gastrointest
Cancer Res. 2008;2(3):113-125.
- Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it
a useful marker of neuroendocrine tumors? J Clin Oncol.
2007;25(15):1967-1973.
- Lloyd RV. Practical markers used in the diagnosis of
neuroendocrine tumors. Endocrine Pathology. 2003:14(4):293-301.
- Creutzfeldt W. Carcinoid tumors: development of our knowledge.
World J Surg. 1996;20(2):126-131.
- Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The
pathologic classification of neuroendocrine tumors. A review of
nomenclature, grading, and staging systems. Pancreas.
2010;39(6):707-712.
- Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic
neuroendocrine tumours. Lancet Oncol. 2008;9(1):61-72.
- Merck Manuals Online Medical Library.
http://www.merckmanuals.com/professional/index.html. 2009. Accessed
December 9, 2010.
How are neuroendocrine tumors (NETs) managed?
How your healthcare team decides to manage your NET depends
on a number of factors. These include:
- The size and location of your tumor
- The grade and stage
of your tumor
- Whether your tumor is functional or nonfunctional
- Any symptoms you may be experiencing
- Quality of life, overall health, and personal considerations
There are several options your doctor has available to treat
NETs. The specific management plan chosen depends on each individual
patient. Options your doctor or other members of your healthcare team
may discuss with you include:
-
Surgery
Surgery is the first option for many patients with NETs. The goal of
surgery is to fully remove a NET or reduce the tumor burden. Your doctor can determine whether or not surgery is right for
you.
-
Chemotherapy and other systemic agents
Systemic therapy involves substances that travel throughout the body in
the bloodstream. Chemotherapy is a systemic therapy that involves the
use of drugs to destroy cancer cells, usually by affecting their
ability to grow. Some chemotherapy agents are used to manage certain
types of NETs. Other systemic agents may be appropriate for patients
depending on the type of NET and treatment goals. Your doctor may
discuss these options with you as part of your personalized management
plan.
-
Chemoembolization
Chemoembolization is a procedure in which the blood supply to a tumor
is temporarily blocked and chemotherapy drugs are administered directly
into the tumor. This procedure is often done to target the primary site
of NET metastases, located in the liver.
-
Radiofrequency ablation
Radiofrequency ablation is a technique in which radio waves are used to
heat and destroy abnormal cells, such as tumor cells. The radio waves
travel through electrodes that can be positioned near the tumor.
-
Radiotherapy
The use of high-energy radiation to destroy cancer cells and shrink
tumors. The radiation may come either from a machine outside the body
or from radioactive material that is placed in the body near cancer
cells.
-
Targeted radionuclide therapy
A radionuclide is a chemical element that releases radiation. In
targeted radionuclide therapy, radionuclides are combined with a
substance that is injected into your body and collects in specific
areas where the tumor is located.
It is also important to remember that NETs sometimes do not
spread or cause symptoms for long periods of time. Because of this, your
doctor may recommend a gradual period during which your disease is
observed.
Your doctor may suggest this strategy, at least initially, if
your NET is causing occasional symptoms that can be controlled with diet
and lifestyle adjustments, or if the risk of surgical or medical
intervention outweighs the benefit. During this time, your doctor may
continue to order tests to monitor your disease.
Are other treatment options being tested or developed?
Clinical studies are being conducted to evaluate new methods for
managing NETs or new ways of using available methods.
You can learn more about clinical studies involving NETs on
ClinicalTrials.gov (www.clinicaltrials.gov), a Web site that lists all
clinical studies currently being conducted throughout the world. The
site gives you information about a study's purpose, who may participate,
locations, and phone numbers for more details. This information should
only be used in conjunction with advice from your doctor.
Your doctor will work with other members of your healthcare team
to determine the best management plan for you. It may be important to be
referred to a NET expert, who has access to the appropriate management
options.
Definitions
- Functional NET:
- A NET that secretes hormones and may cause a variety of
symptoms.
- Grade:
- A system of classifying tumor cells. The cells are graded
based on how abnormal they look under a microscope and how quickly the
tumor is likely to grow and spread. Low-grade tumors (grades 1 and 2)
closely resemble surrounding tissue and are less aggressive. High-grade
tumors (grades 3 and 4) do not resemble surrounding tissue and are more
aggressive.
- Nonfunctional NET:
- A NET that doesn't secrete hormones and may only cause
symptoms due to tumor growth.
- Stage:
- The extent of a cancer in a person's body. Staging is usually
based on the size of the tumor, whether lymph nodes contain cancer, and
whether the cancer has spread from the original site to other parts of
the body.
- Tumor burden:
- A term used to describe the number of cancer cells, the size
of a tumor, or the amount of cancer in a person's body.
References
- Banfield A, Green S, Ramage JK. Neuroendocrine tumor
management: a team approach. Hosp Med. 2005;66(1):37-42.
- Ramage JK, Davies AHG, Ardill J, et al. Guidelines for the
management of gastroenteropancreatic neuroendocrine (including
carcinoid) tumours. Gut. 2005;54(suppl 4):iv1-iv16.
- Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic
neuroendocrine tumours. Lancet Oncol. 2008;9(1):61-72.
- Chambers AJ, Pasieka JL, Dixon E, Rorstad O. The palliative
benefit of aggressive surgical intervention for both hepatic and
mesenteric metastases from neuroendocrine tumors. Surgery.
2008;144(4):645-653.
- National Cancer Institute, Dictionary of Cancer Terms.
http://www.cancer.gov/dictionary/. Accessed December 8, 2010.
- Jensen RT, Doherty GM. Carcinoid tumors and the carcinoid
syndrome. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer:
Principles & Practice of Oncology. 7th ed. Philadelphia, PA:
Lippincott Williams & Wilkins; 2005:1559-1574.
- Merck Manuals Online Medical Library.
http://www.merckmanuals.com/professional/index.html. 2009. Accessed
December 9, 2010.
- Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The
pathologic classification of neuroendocrine tumors. A review of
nomenclature, grading, and staging systems. Pancreas.
2010;39(6):707-712.